Oxpholipin 11D: An anti-inflammatory peptide that binds cholesterol and oxidized phospholipids

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Ruchala, Piotr ^a   Navab, Mohamad ^a   Jung, Chun Ling ^a   Hama Levy, Susan ^a   Micewicz, Ewa D ^a   Luong, Hai ^a,c   Reyles, Jonathan E ^b   Sharma, Shantanu ^b   Waring, Alan J ^a   Fogelman, Alan M ^a   Lehrer, Robert I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHOLESTEROL; CYSTEINE; DEXTRO AMINO ACID; LOW DENSITY LIPOPROTEIN; OXPHOLIPIN 1; OXPHOLIPIN 10; OXPHOLIPIN 11; OXPHOLIPIN 11D; OXPHOLIPIN 12; OXPHOLIPIN 13; OXPHOLIPIN 13D; OXPHOLIPIN 14; OXPHOLIPIN 2; OXPHOLIPIN 3; OXPHOLIPIN 3D; OXPHOLIPIN 4; OXPHOLIPIN 4D; OXPHOLIPIN 5; OXPHOLIPIN 5D; OXPHOLIPIN 6; OXPHOLIPIN 7; OXPHOLIPIN 8; OXPHOLIPIN 9; PEPTIDE D 4F; PEPTIDE DERIVATIVE; PHENYLALANINE; PHOSPHOLIPID; STEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; BACTERIAL PROTEIN; EXOTOXIN; PEPTIDE; PEPTIDE LIBRARY;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOTAXIS; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MOLECULAR DYNAMICS; MONOCYTE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; SURFACE PLASMON RESONANCE; CHEMISTRY; DRUG DESIGN; METABOLISM; PROTEIN BINDING; SYNTHESIS;

MUS; POSIBACTERIA;

ANTI-INFLAMMATORY AGENTS; BACTERIAL PROTEINS; CHOLESTEROL; DRUG DESIGN; EXOTOXINS; PEPTIDE LIBRARY; PEPTIDES; PHOSPHOLIPIDS; PROTEIN BINDING;

EID: 77956306844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010181     Document Type: Article

References (75)

1. Bjorkhem I (2002) Do oxysterols control cholesterol homeostasis? J Clin Invest 110: 725-730.
2. Torocsik D, Szanto A, Nagy L (2009) Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages. Mol Aspects Med 30: 134-152.
3. Olkkonen VM, Hynynen R (2009) Interactions of oxysterols with membranes and proteins. Mol Aspects Med 30: 123-133.
4. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, et al. (2007) 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 13: 1185-1192.
5. Taylor FR, Saucier SE, Shown EP, Parish EJ, Kandutsch AA (1984) Correlation between oxysterol binding to a cytosolic binding protein and potency in the repression of hydroxymethylglutaryl coenzyme A reductase. J Biol Chem 259: 12382-12387.
6. Suchanek M, Hynynen R, Wohlfahrt G, Lehto M, Johansson M, et al. (2007) The mammalian oxysterol-binding protein-related proteins (ORPs) bind 25- hydroxycholesterol in an evolutionarily conserved pocket. Biochem J 405: 473-480.
7. Goldstein JL, Bose-Boyd RA, Brown MS (2006) Protein sensors for membrane sterols. Cell 124: 35-46.
8. Infante RE, bi-Mosleh L, Radhakrishnan A, Dale JD, Brown MS, et al. (2008) Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J Biol Chem 283: 1052-1063.
9. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83: 1505S-1519S.
10. Calder PC (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52: 885-897.
11. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, et al. (2002) Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem 277: 7271-7281.
12. Lewis RA, Austen KF, Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323: 645-655.
13. Tilley SL, Coffman TM, Koller BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 108: 15-23.
14. Boyce JA (2008) Eicosanoids in asthma, allergic inflammation, and host defense. Curr Mol Med 8: 335-349.
15. Capra V, Ambrosio M, Riccioni G, Rovati GE (2006) Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 13: 3213-3226.
16. Peters-Golden M, Henderson WR, Jr. (2007) Leukotrienes. N Engl J Med 357: 1841-1854.
17. Riccioni G, Santilli F, D'Orazio N, Sensi S, Spoltore R, et al. (2002) The role of antileukotrienes in the treatment of asthma. Int J Immunopathol Pharmacol 15: 171-182.
18. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237: 1171-1176.
19. Keane D, Newsholme P (2008) Saturated and unsaturated (including arachidonic acid) non-esterified fatty acid modulation of insulin secretion from pancreatic beta-cells. Biochem Soc Trans 36: 955-958.
20. Claria J (2006) Regulation of cell proliferation and apoptosis by bioactive lipid mediators. Recent Pat Anticancer Drug Discov 1: 369-382.
21. Krishnamoorthy S, Honn KV (2008) Eicosanoids in tumor progression and metastasis. Subcell Biochem 49: 145-168.
22. Moreno JJ (2009) New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochem Pharmacol 77: 1-10.
23. Patel MI, Kurek C, Dong Q (2008) The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 179: 1668-1675.
24. Hirata I, Murano M, Nitta M, Sasaki S, Toshina K, et al. (2001) Estimation of mucosal inflammatory mediators in rat DSS-induced colitis. Possible role of PGE(2) in protection against mucosal damage. Digestion 63 Suppl 1: 73-80.
25. Nieto N, Torres MI, Rios A, Gil A (2002) Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr 132: 11-19.
26. Ku IA, Imboden JB, Hsue PY, Ganz P (2009) Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 73: 977-985.
27. Montecucco F, Mach F (2009) Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 48: 11-22.
28. Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86: 453-460.
29. Back M (2009) Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 23: 41-48.
30. Riccioni G, Capra V, D'Orazio N, Bucciarelli T, Bazzano LA (2008) Leukotriene modifiers in the treatment of cardiovascular diseases. J Leukoc Biol 84: 1374-1378.
31. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a doubleedged sword. Nat Rev Immunol 6: 508-519.
32. Klingenberg R, Hansson GK (2009) Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J.
33. Montecucco F, Mach F (2009) Atherosclerosis is an inflammatory disease. Semin Immunopathol 31: 1-3.
34. Montecucco F, Mach F (2009) Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab 23: 389-400.
35. Montecucco F, Mach F (2009) Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 31: 127-142.
36. Moubayed SP, Heinonen TM, Tardif JC (2007) Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 18: 638-644.
37. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, et al. (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49: 1344-1352.
38. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, et al. (2005) Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25: 1325-1331.
39. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM (2006) Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3: 540-547.
40. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM (2008) Apo A-1 mimetic peptides as atheroprotective agents in murine models. Curr Drug Targets 9: 204-209.
41. Sethi AA, Amar M, Shamburek RD, Remaley AT (2007) Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 8: 201-212.
42. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, et al. (2008) Antiinflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49: 2302-2311.
43. Zhu X, Wu G, Zeng W, Xue H, Chen B (2005) Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J Lipid Res 46: 1303-1311.
44. Chiesa G, Sirtori CR (2003) Apolipoprotein A-I(Milano): current perspectives. Curr Opin Lipidol 14: 159-163.
45. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292-2300.
46. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, et al. (2004) Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109: 3215-3220.
47. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, et al. (2005) Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res 97: 524-532.
48. Navab M, Ruchala P, Waring AJ, Lehrer RI, Hama S, et al. (2009) A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res 50: 1538-1547.
49. Yamaguchi H, Kodama H, Osada S, Kato F, Jelokhani-Niaraki M, et al. (2003) Effect of alpha, alpha-dialkyl amino acids on the protease resistance of peptides. Biosci Biotechnol Biochem 67: 2269-2272.
50. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, et al. (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41: 1495-1508.
51. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, et al. (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99: 2005-2019.
52. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, et al. (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 42: 1096-1104.
53. Anantharamaiah G, Navab M, Reddy ST, Garber DW, Datta G, et al. (2006) Synthetic peptides: managing lipid disorders. Curr Opin Lipidol 17: 233-237.
54. Datta G, Epand RF, Epand RM, Chaddha M, Kirksey MA, et al. (2004) Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem 279: 26509-26517.
55. Epand RM, Epand RF, Sayer BG, Datta G, Chaddha M, et al. (2004) Two homologous apolipoprotein AI mimetic peptides. Relationship between membrane interactions and biological activity. J Biol Chem 279: 51404-51414.
56. Epand RM, Epand RF, Sayer BG, Melacini G, Palgulachari MN, et al. (2004) An apolipoprotein AI mimetic peptide: membrane interactions and the role of cholesterol. Biochemistry 43: 5073-5083.
57. Venkatachalapathi YV, Phillips MC, Epand RM, Epand RF, Tytler EM, et al. (1993) Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins 15: 349-359.
58. Vejux A, Lizard G (2009) Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol Aspects Med 30: 153-170.
59. Poli G, Sottero B, Gargiulo S, Leonarduzzi G (2009) Cholesterol oxidation products in the vascular remodeling due to atherosclerosis. Mol Aspects Med 30: 180-189.
60. Fields GB, Noble RL (1990) Solid phase peptide synthesis utilizing 9- fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35: 161-214.
61. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4: 2411-2423.
62. Gharavi NM, Gargalovic PS, Chang I, Araujo JA, Clark MJ, et al. (2007) Highdensity lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler Thromb Vasc Biol 27: 1346-1353.
63. Fogelman AM, Elahi F, Sykes K, Van Lenten BJ, Territo MC, et al. (1988) Modification of the Recalde method for the isolation of human monocytes. J Lipid Res 29: 1243-1247.
64. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, et al. (1991) Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88: 2039-2046.
65. Johnson WC, Jr. (1990) Protein secondary structure and circular dichroism: a practical guide. Proteins 7: 205-214.
66. Miles AJ, Wien F, Lees JG, Janes RW, Wallace BA (2003) Calibration and standardization of synchrotron radiation circular dichroism and conventional circular dichroism spectrophotometers. Spectroscopy 17: 653-661.
67. Johnson WC (1999) Analyzing protein circular dichroism spectra for accurate secondary structures. Proteins 35: 307-312.
68. Gordon LM, Horvath S, Longo ML, Zasadzinski JA, Taeusch HW, et al. (1996) Conformation and molecular topography of the N-terminal segment of surfactant protein B in structure-promoting environments. Protein Sci 5: 1662-1675.
69. Yamaguchi S, Huster D, Waring A, Lehrer RI, Kearney W, et al. (2001) Orientation and dynamics of an antimicrobial peptide in the lipid bilayer by solid-state NMR spectroscopy. Biophys J 81: 2203-2214.
70. Ulrich AS, Watts A (1994) Molecular response of the lipid headgroup to bilayer hydration monitored by 2H-NMR. Biophys J 66: 1441-1449.
71. Bechinger B, Seelig J (1991) Conformational changes of the phosphatidylcholine headgroup due to membrane dehydration. A 2H-NMR study. Chem Phys Lipids 58: 1-5.
72. Byler DM, Susi H (1986) Examination of the secondary structure of proteins by deconvolved FTIR spectra. Biopolymers 25: 469-487.
73. Roccatano D, Fioroni M, Zacharias M, Colombo G (2005) Effect of hexafluoroisopropanol alcohol on the structure of melittin: a molecular dynamics simulation study. Protein Sci 14: 2582-2589.
74. Hess B, Kutzner C, van der Spoel D (2008) GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput, 4: 435-447.
75. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22: 2577-2637.